UNASSIGNED: We describe the management of @entity1 with newly diagnosed @entity463 ( @entity463 ) in a population-based cohort and compare this to a previously studied cohort. We performed a retrospective cohort study of @entity1 diagnosed with @entity463 from 2006-2008 in Victoria, Australia. @entity1 were identified from the population-based Victorian Cancer Registry and their treating doctors surveyed by questionnaire. Outcomes were then compared to a study of @entity463 @entity1 who were diagnosed between 1998 and 2000 using an identical methodology. We reviewed 351 eligible @entity1 . There were slightly more males (62%) and a minority had @entity66 (13%). Total macroscopic resection, partial resection or biopsy only was performed in 32%, 37% and 24% of @entity1 , respectively. The majority of @entity1 were referred to a radiation oncologist and medical oncologist postoperatively. A total of 56% of @entity1 were treated with postoperative radiotherapy with concurrent and sequential @entity2903 and had a median survival of 14.4months. This was significantly better than @entity1 treated with postoperative radiotherapy alone in the current or earlier cohorts (2006-2008: median survival 6.2months, p<0.0001 versus 1998-2000: 8.9months, p<0.0001). This study demonstrates that @entity86 has become the standard of care in this Victorian population with an associated improvement in median survival.

Management of XXXX in Victoria, Australia (2006-2008).

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity66 :: ('MESH:D004194', 'Disease') :: ['multifocal disease'] @entity86 :: ('MESH:D019106', 'Disease') :: ['postoperative chemoradiation'] @entity2903 :: ('MESH:C047246', 'Chemical') :: ['temozolomide'] @entity463 :: ('MESH:D005909', 'Disease') :: ['glioblastoma multiforme', 'GBM']
@entity463 :: (MESH:D005909,Disease) :: ['glioblastoma']
